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Abstract
The three receptor activity-modifying proteins (RAMPs) have been recognized as being important
for the trafficking and function of a subset of family B G protein-coupled receptors, although the
structural basis for this has not been well established. In the current work, we use morphological
fluorescence techniques, bioluminescence resonance energy transfer, and bimolecular fluorescence
complementation to demonstrate that the secretin receptor associates specifically with RAMP3, but
not with RAMP1 or RAMP2. We use truncation constructs, peptide competition experiments, and
chimeric secretin-GLP1 receptor constructs to establish that this association is structurally-specific,
dependent on the intramembranous region of the RAMP and TM6 and TM7 of this receptor. There
were no observed changes in secretin-stimulated cAMP, intracellular calcium, ERK1/2
phosphorylation, or receptor internalization in receptor-bearing COS or CHO-K1 cells in the presence
or absence of exogenous RAMP transfection, although the secretin receptor trafficks normally to the
cell surface in these cells in a RAMP-independent manner, resulting in both free and RAMP-
associated receptor on the cell surface. RAMP3 association with this receptor was shown to be
capable of rescuing a receptor mutant (G241C) that is normally trapped intracellularly in the
biosynthetic machinery. Similarly, secretin receptor expression had functional effects on
adrenomedullin activity, with increasing secretin receptor expression competing for RAMP3
association with the calcitonin receptor-like receptor to yield a functional adrenomedullin receptor.
These data provide important new insights into the structural basis for RAMP3 interaction with a
family B G protein-coupled receptor, potentially providing a highly selective target for drug action.
This may be representative of similar interactions between other members of this receptor family
and RAMP proteins.
Receptor activity-modifying proteins (RAMPs) are type I single transmembrane proteins that
associate with a subset of G protein-coupled receptors (GPCRs), thereby having the potential
to affect their ligand binding specificity and affinity, signaling, and trafficking (1). In addition
to these potential functional effects, RAMP-GPCR association has been proposed to represent
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an opportunity for the development of highly selective ligands that target this interface,
providing an opportunity to achieve a greater degree of selectivity than those drugs that target
only the particular GPCR molecule (2). However, little is currently understood regarding the
molecular basis of RAMP association with GPCRs or the structural characteristics of the shared
interface between these molecules.
The RAMPs are a family of three proteins, RAMP1, RAMP2, and RAMP3, having
approximately 30 percent amino acid conservation. Each has a relatively large extracellular
amino-terminal region, a single transmembrane segment, and a small intracellular carboxyl-
terminal tail, with RAMP1 and RAMP3 approximately 148 amino acids in length, and RAMP2
having an additional 26 amino acids (3). RAMPs were first identified when they were found
to be responsible for the translocation of the calcitonin receptor-like receptor (CLR) from the
biosynthetic compartments (endoplasmic reticulum and golgi) of the cell to the plasma
membrane (4). Of note, both this receptor and the RAMPS are expressed relatively poorly on
the cell surface in the absence of an appropriate partner molecule. The ability of interacting
GPCRs to enable translocation of RAMPs to the cell surface has become a key feature utilized
in exploring their spectrum of association with other receptors. However, it is particularly
noteworthy that there are currently only a small number of receptors recognized as interacting
with RAMPs, yet RAMPs are expressed in many tissues in which these receptors are absent.
Clearly, more information is needed regarding the basis of RAMP association with other
molecules.
The specific RAMP association with CLR determines its pharmacology. RAMP1/CLR is
phenotypically a calcitonin gene-related peptide (CGRP) receptor; RAMP2/CLR and RAMP3/
CLR exhibit adrenomedullin receptor phenotypes (5). Similarly, RAMP association with the
calcitonin receptor is necessary to express its amylin receptor phenotype (6). Other family B
GPCRs, such as PTH1, PTH2, VPAC1, and glucagon receptors may associate with RAMPs,
but to date no effects on their pharmacological profiles have been reported (7). Of interest, the
VPAC1 receptor can associate with all three RAMPs, while the PTH1 and glucagon receptors
associate only with RAMP2 and the PTH2 receptor associates only with RAMP3 (7,8). Other
family B GPCRs, like the VPAC2, GHRH, GLP1 and GLP2 receptors have not been found to
associate with RAMPs (8). A recent study shows that RAMP1 and RAMP3 can also effectively
interact with the Family C calcium-sensing receptor, where they facilitate receptor
glycosylation and its efficient delivery to the cell surface (9).
In the current work, we identified a new, previously-unrecognized RAMP3-specific interaction
with another family B GPCR, the secretin receptor, and have explored the molecular basis for
this association. This receptor was the first family B GPCR to be isolated, and has been
extensively studied as a prototypical member of this receptor family (10). It is physiologically
important as a mediator of pancreatic and biliary alkaline secretion that is critical for normal
digestion (11). Our experience in working with this receptor, providing extensive insights into
its structure (12,13) and into the molecular basis of its constitutive dimerization (14-18),
provide substantial insights into its function and key resources to explore the basis of its RAMP
association. In the current project, we have utilized fluorescence, resonance energy transfer,
and morphological techniques to establish the presence of a structurally-specific association
between RAMP3 and the secretin receptor, and have localized the basis of this interaction to
an intramembranous region of the RAMP and specifically to TM6 and TM7 of this receptor.
EXPERIMENTAL PROCEDURES
Receptor constructs
RAMP constructs fused in-frame at their carboxyl terminus with Renilla luciferase (Rlu) or
yellow fluorescent protein (YFP) were prepared using GATEWAY technology from
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Invitrogen (Carlsbad, CA). The cDNAs encoding each human RAMP (RAMP1, RAMP2 and
RAMP3) were amplified with Expand High Fidelity Enzyme blend (Roche) using a forward
primer that introduced four nucleotides (CACC) immediately before the ATG initiation codon
and a reverse primer that removed the receptor’s natural stop codon. The PCR products were
subcloned into the pENTR/D-TOPO vector using the pENTR directional TOPO Cloning Kit
(Invitrogen), following the manufacturer’s recommendations. The destination vectors were
generated using the GATEWAY Vector conversion system, as previously described (15). The
recombination reactions between pENTR-specific receptor cDNA and the destination vectors
(pCR3.1-Rlu-dest and pEYFP-N1-dest) were performed using the LR recombinase kit.
Additional RAMP constructs were prepared by inserting the amino- or carboxyl-terminal YFP
fragments, YFP(1-158) (YN) or YFP(159-238) (YC), respectively, into the BglII/HindIII
restriction sites before the TGA stop codon. The Δ(10-100) RAMP3 construct was created by
inserting two XbaI sites after the relevant codons using the QuikChange site-directed
mutagenesis kit (Stratagene, La Jolla, CA). The nucleotide sequence between these sites was
excised to yield RAMP3 sequences lacking 90 amino acids.
Amino- and carboxyl-terminal-truncated secretin receptor constructs, Rlu- and YFP- tagged
human secretin receptor (SecR) constructs, the CLR receptor construct, and an Rlu- tagged
CTR construct have been prepared previously (16,18). Cmyc-tagged secretin receptor was
prepared by primer extension PCR. cDNAs for N-ethylmaleimide-sensitive factor (pCMV6-
NSF) and sodium-hydrogen exchange regulatory factor (pCMV6-NHERF1) were purchased
from Origene (Rockville, MD). The secretin receptor mutant in which Gly241 within TM4 was
replaced with Cys (G241C) was prepared by oligonucleotide-directed mutagenesis. All
sequences were confirmed by direct DNA sequencing.
Chimeric secretin-GLP1 receptor constructs were prepared by fusion of complementary
fragments of the two receptors, replacing segments of the secretin receptor with corresponding
segments of the GLP1 receptor, again verifying the resulting sequences. Constructs consisted
of the following: (SecR1-124)(GLP1R121-230)(SecR223-419) substituting the TM1-TM3 region
of the secretin receptor with the corresponding region of the GLP1 receptor, denoted Sec
(GLP1TM1-3)R; (SecR1-230)(GLP1R232-311)(SecR302-419) substituting the TM4-TM5 region
of the secretin receptor with the corresponding region of the GLP1 receptor, denoted Sec
(GLP1TM4-5)R; and (SecR1-309)(GLP1R319-388)(SecR377-419) substituting the TM6-TM7
region of the secretin receptor with the corresponding region of the GLP1 receptor, denoted
Sec(GLP1TM6-7)R. Each of these constructs expressed in intact cells was shown to bind secretin
and to signal normally, establishing their abilities to be synthesized and to traffick normally to
the cell surface where their architecture was intact and able to couple with Gs (see data below).
Peptides
Synthetic peptides corresponding to each of the predicted transmembrane segments of the
human secretin receptor were synthesized as described previously (17). This was achieved by
manual solid-phase techniques using Pal resin (Advanced Chem Tech) and FMOC-protected
amino acids. The peptides were purified to homogeneity using reversed-phase HPLC with an
octadecylsilane reversed-phase column. Resulting peptides had their identities verified by mass
spectrometry. For use, they were solubilized in dimethyl sulfoxide (DMSO) prior to dilution
with KRH medium to yield a final concentration of 0.1% DMSO, with this concentration of
DMSO shown to have no effect in the relevant assays.
Cell culture and transfection
African green monkey kidney (COS) cells obtained from the American Type Culture
Collection (ATCC) (Manassas, VA) were propagated in tissue culture plasticware in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented
Harikumar et al. Page 3













with 5 % Fetal Clone II (Hyclone laboratories, Logan, UT) in a humidified environment
including 5 % CO2. They were passaged approximately twice per week. For interaction studies,
cells were transfected using the modified diethylaminoethyl (DEAE)-dextran method (17) and
were studied approximately 72 h after transfection. For functional studies, COS cells were
seeded at a density of 30,000 per well in a 96-well plate using DMEM supplemented with 10
% (v/v) Fetal bovine serum (FBS) 24 h prior to transfection. Transfection of cmyc-tagged
secretin receptor, RAMPs, NSF, and NHERF1 plasmids was performed according to cell type-
specific recommendations in the Metafectine transfection reagent manual (Biontex
Laboratories, GmbH). Chinese hamster ovary (CHO) K1 cells (American Type Culture
Collection) were cultured in complete media (5 % FBS, DMEM) and seeded into 75 cm2 culture
flasks to achieve approximate 90 % cellular confluency the next day. These cells were then
transfected with cmyc-secretin receptor and human RAMP1, RAMP2 or RAMP3 DNA. DNA
lipid complexes were formed in 1 ml serum-free OPTIMEM1 (Invitrogen, Carlsbad, CA) using
1.6 γg of human secretin receptor and 11.4 γg of human RAMPs or pcDNA3.1 as mock control,
along with 60 γl of Lipofectamine 2000 (Invitrogen, Carlsbad, CA). After 45 min, DNA-lipid
complexes were added to flasks of cells already containing 4 ml of serum-free OPTI-MEM1.
The cells were left to be transfected overnight or for 15 h. Cells were then recovered for 8 h in
complete medium and subsequently passaged and seeded into 96-well plates and 25 cm2 culture
flasks to achieve 60-90 % confluency for use the following day in functional assays.
Confocal fluorescence microscopy
Possible RAMP association with GPCRs was studied in a morphologic translocation assay in
which fluorescent RAMP was evaluated for movement from the endoplasmic reticulum to the
plasma membrane. In this assay, COS cells were transiently transfected with both the RAMP
and GPCR constructs. After 24 h, the cells were seeded onto UV-sterilized 25-mm coverslips,
washed with phosphate-buffered saline (PBS) and fixed in 2 % (w/v) paraformaldehyde (in
PBS) for 30 min at room temperature. Cells were then washed with PBS before being mounted
on a microscope slide using vectashield. YFP fluorescence was observed using a Zeiss LSM
510 confocal microscope (Thornwood, NY) with excitation, 488 nm argon laser; emission,
LP505 filter; pinhole diameter 2.6 airy units, Plan-Apochromat 63X/1.4NA oil. Background-
subtracted images were collected and assembled using Adobe Photoshop 7.0 (Mountain View,
CA). Fluorescent labeling of secretin receptors on receptor-expressing cells were carried out
by incubating the cells with 50 nM secretin(1-27)-Gly-Cys- Alexa488 (Alexa-secretin) (19) in
PBS containing 0.08mM CaCl2 and 0.1 mM MgCl2 at 4°C for 90 min. After the incubation,
the cells were washed twice with ice-cold PBS and fixed with 2% paraformaldehyde priior to
being mounted on a slide using vectashield. The Alexa fluorescence was observed using an
epifluorescence Zeiss microscope with an FITC filter set (excitation, 480/20 nm; dichroic
mirror, Q515 lp; and emission, 535/30 nm).
BRET studies
Molecular associations were further evaluated using a bioluminescence resonance energy
transfer (BRET) assay. In this, measurements were performed with a suspension of
approximately 25,000 COS cells expressing relevant fluorescently-tagged constructs in 96-
well white Optiplates, as described previously (17). The measurements were initiated by adding
the cell-permeant Renilla luciferase-specific substrate, coelenterazine h (Biotium, Hayward,
CA), to achieve a final concentration of 5 μM. The resultant BRET signals were collected using
the 2103 Envision fluorescence plate reader (PerkinElmer, Wellesley, MA) set up with the
<700 nm mirror and with emission filter sets for luminescence (460 nm, bandwidth 25 nm)
and fluorescence (535 nm, bandwidth 25 nm). The BRET ratios were calculated based on the
ratio of emissions, as described previously (17).
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Saturation BRET experiments were performed for validation of the BRET signals, as described
previously (17). Here, COS cells were transfected with a constant amount of donor construct
(Rlu-tagged construct at 1.0 μg DNA/dish) and with increasing amounts of acceptor construct
(YFP-tagged construct, ranging from 0.3 μg to 6 μg DNA/dish). BRET assays were performed
48 h after transfection. The BRET data were analyzed and were evaluated for quality-of-fit
based on R2 values using Prism 3.0 (GraphPad Software, San Diego, CA).
Bimolecular fluorescence complementation
Bimolecular fluorescence complementation assays were carried out in COS cells transiently
expressing YN- and YC-tagged constructs. The COS cells were transfected with equimolar
concentrations of YN-tagged secretin receptor and YC-tagged RAMP3 constructs. Twenty
four hr after transfection, the cells were lifted using 0.05 % trypsin and were plated onto UV-
sterilized cover slips and allowed to grow for 48 h before being fixed and mounted on a
microscopic slide for fluorescence microscopy using standard YFP settings, as described
above.
Functional assays
Cells were harvested 16 h after transfection and seeded for use in cAMP, ERK1/2
phosphorylation, and calcium mobilization assays, or for antibody-binding experiments. Cells
were allowed to adhere for 16 h, followed by serum-starvation for an additional 24 h prior to
use in the functional assays.
Measurement of cAMP
Intracellular cAMP levels were determined using either AlphaScreen methodology with Fusion
plate reader (PerkinElmer, Wellesley, MA) (20) or LANCE methods with Envision plate reader
(PerkinElmer) (17), as have been fully described and validated in the respective laboratories
previously. Each data point was assayed in duplicate, and the quantity of cAMP generated was
calculated from the raw data using a cAMP standard curve. Results are expressed as the means
± S.E.M. of data from three independent experiments.
Calcium mobilization assay
Transfected cells were seeded in poly-L-lysine-coated 96-well plates at a density of 50,000
cells/well, incubated overnight and serum-starved for an additional 24 h. Cells were washed
three times with a modified Hanks buffered-saline solution (HBSS) (containing (in mM): NaCl,
150; KCl, 2.6; MgCl2, 1.18; D-glucose, 10; HEPES, 10; CaCl2, 2.2; probenecid, 2 and 0.5 %
(w/v) BSA. In light-diminished conditions, 100 μl of wash solution was added containing the
cell-permeant calcium fluorophore, Fluo-4/AM (10 μM) and incubated for 1 h at 37 °C. The
fluorophore solution was aspirated from the wells, and cells were washed twice then incubated
for 30 min in modified HBSS at 37 °C. The assay plate was transferred to a FlexStation
(Molecular Devices, Palo Alto, CA), which performed the robotic addition of ligands (10 ×
stocks in modified HBSS). Receptor-mediated changes in intracellular calcium concentration
were immediately recorded by the FlexStation using an excitation wavelength of 485 nm and
emission wavelength of 520 nm. Data were collected for each well every 1.52 s for a total of
135 s.
ERK1/2 phosphorylation assay
Transfected cells were seeded in 96-well plates at a density of 50,000 cells/well, and incubated
for 16 h prior to being serum-starved overnight. On the day of assay, cells were pre-treated
with buffer or inhibitors (at the concentrations specified) and then stimulated with agonist at
37 °C. Time-course results demonstrated a peak response at 10 min for all receptor complexes
following agonist stimulation; this time point was subsequently used in concentration-response
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studies. ERK1/2 phosphorylation was measured using the AlphaScreen-based ERK1/2
SureFire assay kit as previously described (21). Data are expressed as the percent response
relative to stimulation with 10 % FBS.
Determination of cell-surface expression of receptors using enzyme-linked immunosorbent
assay
COS and CHO-K1 cells were transfected as described above. All receptor constructs
incorporated a cmyc epitope tag at the amino terminus, which enabled cell-surface expression
to be determined by enzyme-linked immunosorbent assay as described previously (22). Results
were normalized against data from non-transfected cells. All experiments were performed in
quadruplicate.
Internalization assay
Cells transfected with cmyc-secretin receptor, RAMPs, NSF or NHERF1 were used for an
enzyme-linked immunosorbent assay-based internalization assay in which the surface
expression of the secretin receptor was assessed at 1, 2, 3, 4, 6, 8, 10 s and then at 5 min intervals
for 60 min after exposure to 100 nM secretin. Internalization profiles of cells transfected with
cmyc-secretin and RAMPs were compared in the presense or absence of either NSF or
NHERF1.
Data Analysis
cAMP, ERK1/2 phosphorylation, and calcium mobilization concentration-response data were
analyzed via nonlinear regression using PRISM version 5 (GraphPad Software, San Diego,
CA). In all instances, data points are shown as the mean ± S.E.M.
RESULTS
Cellular translocation assay for possible interactions between RAMPs and the secretin
receptor
The classical assay for RAMP association with a GPCR involves the demonstration of the
ability of the receptor to translocate the fluorescent RAMP from the biosynthetic compartment
to the plasma membrane (4,7). We performed this assay with COS cells transiently expressing
fluorescent RAMPS and the secretin receptor, using CLR (known to associate with all three
RAMPs) as a positive control. Shown in Figure 1 are COS cells transfected with YFP-tagged
RAMP constructs in the absence or presence of GPCR constructs. In the absence of receptor
co-transfection (left column), the fluorescent RAMPs all remained in the biosynthetic
compartments, particularly the endoplasmic reticulum. Following, co-transfection with CLR
(right column), the fluorescent RAMP signals were clearly observed at the plasma membrane,
demonstrating the known effect of association between the RAMPs and that receptor.
Analogous experiments with the secretin receptor (middle column) generated a similar
fluorescence signal at the plasma membrane for RAMP3, but none for RAMP1 or RAMP2.
This suggests that the secretin receptor can interact in a structurally-specific manner with
RAMP3. This had not previously been observed or reported.
BRET studies of possible RAMP interactions with the secretin receptor
We also utilized resonance energy transfer studies to examine the possible interactions between
RAMPs and the secretin receptor (Fig 2A). In these studies, Rlu-tagged secretin receptor was
used as donor and YFP-tagged RAMP constructs were used as possible acceptors. The well-
established interactions between the calcitonin receptor and all three RAMPs (3) were used as
positive controls in this series of studies. Indeed, in this assay, the calcitonin receptor expressed
with RAMP1, RAMP2, or RAMP3 each generated a strong BRET signal above background;
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the latter established by the co-expression of RAMP-Rlu with cytosolic YFP. Of note, a similar
positive BRET signal was generated by the co-expression of the secretin receptor with RAMP3.
In contrast, the secretin receptor co-expressed with RAMP1 or RAMP2 did not produce a
significant BRET signal above background. These data confirm the apparent structurally-
significant interaction between the family B G protein-coupled secretin receptor and RAMP3
that was suggested by the cellular translocation assay data.
The static BRET assay results were further validated using saturation BRET studies. Saturation
BRET studies were performed to distinguish a specific and saturable molecular interaction
between the secretin receptor and RAMP3, in contrast to a random molecular association
between the donor and acceptor in a crowded cellular compartment. Figure 2B shows the BRET
signals typical of a specific interaction in COS cells expressing a fixed concentration of donor
construct (SecR-Rlu) with increasing amounts of acceptor construct (RAMP3-YFP), with the
BRET signal increasing and then reaching a plateau. This was similar to the positive control
that was generated when the calcitonin receptor was co-expressed with RAMP1, RAMP2, or
RAMP3. In contrast, the BRET signals reflecting possible secretin receptor interaction with
RAMP1 were not different from a linear fit through the origin, as is typical of a non-specific
interaction.
The agonist-dependency of the interaction between the secretin receptor and RAMP3 was also
studied using an analogous BRET assay (Fig 2C). There was no significant effect of ligand
occupation on the signal in this assay using stimulation with secretin concentrations as high as
1 μM.
Bimolecular fluorescence complementation to demonstrate secretin receptor-RAMP3
interactions
The bimolecular fluorescence complementation approach was used to further demonstrate the
specific interaction between the secretin receptor and RAMP3 (Fig 3). RAMP3-YFP expressed
in the absence of receptor transfection was observed to reside in cellular biosynthetic
compartments, particularly the endoplasmic reticulum. When RAMP3 was tagged with YN or
YC, no fluorescence was observed. However, when RAMP-YN and RAMP-YC were co-
expressed, the fluorescence pattern was similar to that of RAMP3-YFP, consistent with the
ability of RAMP molecules to dimerize, as has been reported (3), yet this signal was limited
to the intracellular biosynthetic compartments. When the non-fluorescent SecR-YN construct
was co-expressed with the RAMP3-YC construct, a fluorescent signal was observed at the
level of the plasma membrane. This pattern of response was similar to that observed when
analogous studies were performed with the known RAMP3 partner, the calcitonin receptor,
representing a positive control for this assay.
Exploring the region of the secretin receptor that contributes to its interaction with RAMP3
To explore the molecular basis for the interaction between the secretin receptor and RAMP3,
BRET and cellular translocation studies were performed with truncated receptor constructs. In
the static and saturation BRET studies, secretin receptor constructs with truncation of the
amino-terminal region (residues 1-121) or truncation of the carboxyl-terminal region (residues
376-419) displayed similar levels of energy transfer to those observed with the intact wild type
secretin receptor, suggesting that the terminal regions were not critical for RAMP association
with this receptor (Fig 4A and 4B). Morphological translocation studies of fluorescently-tagged
RAMP3 were also consistent with the BRET data (Fig 5).
The possible contribution of the transmembrane (TM) helical bundle region of the secretin
receptor to its interaction with RAMP3 was explored using a different experimental strategy.
In this, peptides representing each of the TM segments were used to compete for a critical
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epitope in the bimolecular fluorescence complementation assay with YN-tagged RAMP3 and
YC-tagged secretin receptor that normally yields fluorescence at the level of the plasma
membrane. When a critical epitope for interaction between the secretin receptor and RAMP3
would be delivered to this system, the plasma membrane fluorescence would be expected to
be reduced or eliminated. Indeed, as observed in Figure 6, this was the case for the peptides
encompassing TM6 and TM7. Each of the other secretin receptor TM segment peptides elicited
no competitive disruption of this signal.
To further confirm these observations, receptor chimeras were created between the GLP1
receptor that is known to not associate with any RAMP (7), and the secretin receptor. These
chimeric receptor constructs trafficked normally and were structurally and functionally intact,
as reflected by their abilities to bind and signal in response to secretin. The following
concentrations of secretin (nM) were able to stimulate half-maximal cAMP responses in COS
cells expressing the respective constructs, as determined by the LANCE methodology (17):
SecR, 0.4±0.15; Sec(GLP1TM1-3)R, 4.4±0.12 ; Sec(GLP1TM4-5)R, 5.9±1.84; and Sec
(GLP1TM6-7 )R, 6.8±1.1. Basal levels of cAMP in these cells were 2.1±0.5 picomoles per
million cells, while maximal levels achieved (Emax values) represented the following for each
construct were: SecR, 178±24; Sec(GLP1TM1-3)R, 153±14; Sec(GLP1TM4-5)R, 149±15; and
Sec(GLP1TM6-7)R, 165±15 picomoles per million cells. As predicted by the competitive TM
peptide approach, only the chimeric constructs incorporating the secretin receptor TM6 and
TM7 regions were able to translocate the fluorescent RAMP3 construct (Fig 7). The chimeric
secretin receptors incorporating TM1-TM3 and TM4-TM5 regions of the GLP1 receptor
behaved like the wild type secretin receptor, transporting the fluorescent RAMP3 construct to
the cell surface. However, when the TM6-TM7 regions of the GLP1 receptor were included
in the chimeric construct, this RAMP remained intracellularly in the biosynthetic compartment.
Exploring the region of RAMP3 that contributes to its interaction with the secretin receptor
RAMP3 is a type I single transmembrane protein that has a large extracellular amino-terminal
region and a very small intracellular carboxyl-terminal region. In this series of studies, most
of the amino-terminal tail of RAMP3 was deleted (residues 10-100). This was studied in BRET
and morphological translocation assays using YFP-tagged (Δ10-100)RAMP3 and Rlu-tagged
secretin receptor in COS cells. Figures 8A and 8B show that this RAMP3 deletion construct
behaved like wild type RAMP3, suggesting that the amino terminus does not contribute
significantly to the molecular association. This was further supported by the morphologic
translocation assay where (Δ10-100)RAMP3 retained the ability to translocate to the cell
surface when co-expressed with the secretin receptor (Fig 8C).
Functional assays
RAMP-receptor interaction, in a receptor-specific and RAMP-specific manner, has been
proposed to alter ligand recognition (4,6), signal strength and preference (7,23) and receptor
internalization and recycling (24,25). We therefore sought to determine if interaction of
RAMP3 with the secretin receptor could alter gross receptor function in signaling and
internalization assays, in two cellular backgrounds (COS and CHO-K1 cells). It must be
remembered, however, that the secretin receptor is capable of trafficking normally to the
plasma membrane even in the absence of RAMPs. Thus, unlike the early functional assays
using CLR where only RAMP-associated receptor reaches the plasma membrane, here RAMP-
free and RAMP3-associated secretin receptor are present on the cell surface. In COS cells,
RAMP3 co-expression did not alter secretin-induced increases in cAMP production,
intracellular calcium mobilization, or phosphorylation of ERK1/2 (Table 1). Similarly,
transient co-expression of the secretin receptor with each individual RAMP failed to elicit any
specific change in these parameters, except for RAMP1 where a decrease in secretin potency
in the COS cell cAMP assay was observed (Table 1) (20). No difference in intracellular calcium
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mobilization or cAMP response was observed in CHO-K1 cells upon co-transfection with any
of the RAMPs (Table 1). The lack of consistent effect by RAMP1 on cAMP response across
the two cellular backgrounds suggests that the effect in COS cells is a nonspecific response of
these cells, potentially via altered Gαs levels. We further monitored internalization of cmyc-
tagged secretin receptor in response to 100 nM secretin peptide. In CHO-K1 cells expressing
the secretin receptor alone, secretin induced a rapid internalization of the receptor, with a t1/2
of ~1.5 min. Co-expression of individual RAMPs did not alter the rate or extent of receptor
internalization (Fig 9A). Furthermore, additional co-expression of either NSF, or NHERF1,
which modify the internalization or recycling of the RAMP3-based adrenomedullin 2 receptor
(24,25), failed to affect secretin receptor internalization, either alone or in the presence of
RAMP3 (Fig 9B,C). Cell surface expression of the cmyc-tagged secretin receptor, as
determined by enzyme-linked immunosorbent assay, was not significantly different between
receptor expressed alone or receptor expressed in the presence of RAMPs (data not shown).
Additional studies were performed to further explore potential function of the RAMP3-secretin
receptor association. In the first series of these studies, a secretin receptor mutant in which
Gly241 in TM4 was replaced with Cys (G241C), resulting in a receptor mutant that did not
traffick normally to the plasma membrane. This construct was trapped in the biosynthetic
machinery, likely the endoplasmic reticulum (26). In the presence of RAMP3, this defect was
partially corrected, resulting in more receptor trafficking to the plasma membrane and the
emergence of demonstrable biological activity in response to secretin stimulation in intact cells
(Fig 10). Furthermore, the transfection of increasing amounts of the secretin receptor along
with constant amounts of CLR and RAMP3 resulted in attenuation of the adrenomedullin
response (Fig 11), with a parallel loss of CLR at the cell surface as monitored by ELISA (data
not shown). This suggests that the secretin receptor was able to compete with CLR for RAMP3,
resulting in less CLR-RAMP3 adrenomedullin receptor complex at the cell surface.
DISCUSSION
RAMPs were first discovered based on their function in an expression cloning strategy, seeking
a calcitonin gene-related peptide (CGRP) receptor (4). It ultimately became clear that an
accessory protein was necessary to be combined with the calcitonin receptor-like receptor
(CLR) to facilitate its glycosylation and trafficking to the cell surface where it could bind and
be activated by CGRP. This accessory protein was the first RAMP. This same type of survey
was subsequently successful in identifying RAMP partners for the calcitonin receptor (CTR)
and for the CLR, to provide molecular complexes that respond to amylin or adrenomedullin
as well.
With both of these early recognized RAMP partners identified as family B GPCRs, many other
members of the family have been screened for RAMP association. This was largely dependent
on a fluorescent RAMP translocation assay in which receptor interaction with the RAMP, in
transit through the biosynthetic compartments, leads to translocation of the RAMP to the
plasma membrane. Indeed, this approach has been successful in demonstrating RAMP- and
receptor-specific interactions where the PTH1, PTH2, VPAC1, and glucagon receptors all
associate with one or more RAMPs, while the VPAC2, GHRH, GLP1 and GLP2 receptors do
not appear to associate with any RAMPs (7,8). More recently, association of RAMP1 and
RAMP3 with the calcium-sensing receptor has been reported (8). Despite this growing list of
RAMP-receptor interactions, relatively little is known regarding the molecular mechanism(s)
underlying the interaction. In the current study, we have identified the secretin receptor as a
novel, specific partner for RAMP3 and have elucidated the interaction interface as TM6 and
TM7 of the receptor.
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To date, the best studied RAMP-GPCR interaction is that of CLR and RAMP1. For this
receptor, a major component of the interaction interface is believed to be the amino-terminal
domain of the receptor. Both the isolated amino-terminal domain of RAMP1 and the amino-
terminal domain of RAMP1 linked to platelet-derived growth factor (PDGF) receptor
transmembrane region are capable of eliciting cell surface expression of CLR and to engender
a CGRP receptor phenotype (27). This is further supported by loss of cell surface expression
of CLR following mutagenesis of specific aromatic amino acids in helix 3 of the RAMP1 amino
terminus (1,2). A similar interaction between CLR and RAMP2 and RAMP3 is also likely as
mutation of conserved amino-terminal histidine residues in these proteins also disrupts the
ability of RAMPs and CLR to translocate to the cell surface, although the specific role of
individual histidines can differ between RAMPs (28). Nonetheless, the RAMP transmembrane
region also played a contributory role in the interaction with CLR with both the isolated amino-
terminal domain and the RAMP1-PDGF receptor chimera unable to fully reconstitute RAMP1
function (27).
The critical role of the amino-terminal domains of CLR and the RAMPs contrasts with the lack
of importance of these domains for interaction between the secretin receptor and RAMP3
observed in the current study. Deletion of either the secretin receptor amino terminus or the
RAMP3 amino terminus had little effect on trafficking of RAMP3 to the cell surface. Use of
isolated receptor transmembrane peptides and chimeras between the secretin receptor and the
GLP1 receptor refined the key site of interaction to TM6 and TM7. A key role for the
transmembrane region of RAMPs in receptor interaction has also been observed for the CTR
where chimeras of RAMP1 and RAMP2 implicated the transmembrane region as the key
determinant of the difference in strength of induction of amylin receptor phenotype (29,30),
however, the site of this interaction within the CTR has not been determined.
Phenotypically, all GPCR-RAMP interactions identified to date enable cell surface
translocation of intracellularly retained RAMPs, which is not surprising as this is the underlying
tenet for most assays for interaction. However, despite their initial description as modulators
of peptide-binding specificity in association with CLR (4), the alteration of binding profiles
has only been observed for CLR and the closely-related CTR (1,2). For other interacting
receptors, including the VPAC1 and PTH1 receptor, no effect on peptide affinity has been
observed (7). A similar lack of effect by RAMP3 on secretin interaction with its receptor was
found in the current study, with no apparent change in secretin potency across a broad range
of assays including cAMP accumulation, intracellular calcium mobilization and
phosphorylation of ERK1/2.
As with most receptors, the secretin receptor does not require RAMP co-expression for cell
surface expression. Therefore, we cannot rule out the possibility that the lack of a specific
demonstrable signaling phenotype in these assays is due to the expression of “uncomplexed”
secretin receptor at the cell surface that overwhelms the response of RAMP3-secretin receptor
complexes, since the percentage of complexed and uncomplexed receptor is unknown.
However, under the varying conditions of assay for BRET and bimolecular fluorescence
complementation, the level of interaction between RAMP3 and the secretin receptor was
similar to that seen for CLR or CTR interaction with RAMP3, the classic RAMP-associating
receptors. For the CTR, this level of interaction clearly enables resolution of signaling from
uncomplexed and complexed receptor despite a high level of background uncomplexed CTR
phenotype (6,23,29,31).
Functional consequence of the secretin receptor-RAMP3 interaction was demonstrated in two
additional assays. In the first series of studies, a trafficking-defective secretin receptor mutant
was rescued by RAMP3 co-expression. This suggests that the RAMP can play a chaperone-
like role for an interacting receptor, even when this is not required for routine cell surface
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receptor expression. In the second series of studies, secretin receptor competed for the RAMP3
interaction with CLR, an interaction that is critical for the establishment of a functional
adrenomedullin receptor. Thus, we also need to be cognizant of how interacting molecules
might saturate and compete for other functionally-important molecular associations.
The lack of effect in modulation of apparent secretin affinity is consistent with the lack of
interaction between the amino-terminal domains of the secretin receptor and RAMP3. Indeed,
it implies that lack of significant association between the amino-terminal domains may be the
norm rather than the exception for most family B GPCR-RAMP interactions. The identification
of TM6 and TM7 as the secretin-RAMP3 interface is therefore the first mechanistic guide to
how most RAMP-family B receptor associations may occur.
Of note, the RAMP-secretin receptor interface is distinct from the homodimerization interface
for secretin receptors that we recently identified as TM4 of this receptor (17).
Homodimerization of the secretin receptor appears to be important for efficient signaling of
the receptor (17), and our current data are consistent with an ability of RAMP3 to interact with
an intact secretin receptor homodimer. For the CLR, elegant work has revealed that it is also
a homodimer of this receptor that interacts with RAMPs, with the RAMP present as a monomer
(32), although the final stoichiometry of the complex is not clear. Assuming that there is
conservation of function across family B GPCRs, these data provide support for the potential
extrapolation of our current findings as a model for RAMP-family B GPCR transmembrane
region interactions, however, an alternate interface involving TM1 and TM2 of CLR cannot
be ruled out.
The other key RAMP-dependent phenotype that has been observed for CLR-RAMP3
interactions is an alteration to adrenomedullin-induced internalization and recycling of the
AM2 receptor (24,25). The AM2 receptor, but not the RAMP2-associated AM1 receptor, may
be alternatively targeted for lysosomal degradation, rapidly recycled or not internalized at all
depending upon interaction of the carboxyl-terminal RAMP3 PDZ domain with either NSF or
NHERF1. Consequently, we studied internalization of the secretin receptor in the presence and
absence of RAMPs and also in the context of overexpression of either NSF or NHERF1.
However, internalization of the secretin receptor was not altered by RAMP3, either alone or
in the presence of NSF or NHERF1, suggesting that the protein-protein interactions engendered
by RAMP3 are contextual on the presentation of the PDZ epitope by its receptor partner.
The resolution of the site of transmembrane interaction between RAMP3 and the secretin
receptor provides impetus towards understanding the molecular basis for the specificity of
RAMP-GPCR interactions. If this interaction interface is confirmed for other GPCRs, it will
enable a bioinformatic approach to prediction of RAMP-GPCR interactions. For example, the
secretin receptor and the PTH2 receptor specifically interact with RAMP3, while the PTH1
and glucagon receptors specifically interact with RAMP2. There has been substantial work to
explore the molecular basis of helix-helix interactions within the lipid bilayer (33-35). Within
the helical domain of the three RAMPs, there is approximately 30 percent identity of the amino
acid residues and 60 percent homology. The differences between the RAMPs should be
adequate to explain the specificity of interaction between a given GPCR and a given RAMP.
Conservation of the site of transmembrane interaction would therefore allow rules to be
developed for predicting such interactions.
Our data also provides further evidence for complexity in the functional consequence of
RAMP-GPCR interaction with existing phenotypes varying greatly across interacting receptors
and also many examples of lack of understanding of the functional significance of RAMP-
GPCR interaction, as currently is the case for the secretin receptor-RAMP3 interaction. The
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broad distribution of RAMPs suggests that substantial work is still required to fully understand
their role in physiology and disease.
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GPCR G protein-coupled receptor
GLP glucagon-like peptide
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RAMPs receptor activity-modifying proteins
Rlu Renilla luciferase
SecR human secretin receptor
VPAC vasoactive intestinal polypeptide receptor
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FIGURE 1. Morphologic assays for RAMP translocation to the plasma membrane
Shown are fluorescence images of the expression of each type of RAMP in COS cells, all
localized to biosynthetic compartments, particularly representing the endoplasmic reticulum
(left column). The right column shows the changes in distribution of the fluorescence when
the calcitonin receptor-like receptor was co-expressed with each YFP-tagged RAMP. In all
three conditions, there was significant translocation to the plasma membrane (highlighted with
arrowheads). The middle column shows the changes in distribution of the fluorescence when
the secretin receptor was co-expressed with each RAMP. Here, only RAMP3 distribution was
changed, with significant translocation to the plasma membrane (highlighted with arrowheads).
Insets show the boxed regions at higher magnification. The images shown are representative
of four similar experiments. Bar 25 μm.
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FIGURE 2. BRET analysis of association between RAMPs and the secretin receptor
Shown are BRET signals in static and saturation assays evaluating the potential interaction of
the secretin receptor and RAMPs. In the static assays shown in panel A, background BRET
signals were determined by expression of the Rlu-tagged RAMPs and soluble YFP. The co-
expression of YFP-tagged RAMP1 and RAMP2 produced only background BRET. In contrast,
co-expression of RAMP3 produced a significant BRET signal. This was similar to that
produced by the positive control, the co-expression with the Rlu-tagged calcitonin receptor.
Panel B shows the saturation BRET data, confirming the significance of the signal generated
by co-expression of RAMP3 and the secretin receptor. In panel C, the effects of increasing
concentrations of secretin on the BRET signal were studied. The cells were incubated with
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specified concentrations of secretin at 37°C for 5 min before adding the coelenterazine h
(5μM) to initiate the BRET signal. There was no significant effect of agonist on secretin
receptor-RAMP3 interaction. The values plotted represent means ± S.E.M. of data from five
independent experiments. ** p<0.001 significantly above background BRET signals.
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FIGURE 3. Bimolecular fluorescence complementation assays
Shown are typical fluorescence images of COS cells expressing the YFP-, YN-, and YC-tagged
constructs, as noted. Significant fluorescence was noted at the cell surface (highlighted with
arrowheads) when YC-tagged RAMP3 was co-expressed with the calcitonin receptor tagged
with YN or with the secretin receptor tagged with YN. RAMP dimerization in the intracellular
biosynthetic compartments was observed when RAMP-YN and RAMP-YC were co-
expressed. Insets show the boxed regions at higher magnification. Bar 25 μm.
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FIGURE 4. BRET analysis of secretin receptor-RAMP3 interaction using truncated receptor
constructs
Shown are the static (A) and saturation (B) BRET signals obtained from COS cells
coexpressing Rlu-tagged truncated secretin receptor with YFP-tagged RAMP3. Significant
BRET signals above non-specific (shown in the shaded area) are marked *p<0.01, **p<0.001.
The values plotted represent means ± S.E.M. of data from five independent experiments.
Harikumar et al. Page 19













FIGURE 5. Morphological RAMP translocation assay
Shown are representative confocal microscopic images of COS cells expressing either YFP-
tagged RAMPs alone or co-expressed with wild type or amino-terminal region (Δ1-121)
truncated or carboxyl-terminal region (Δ376-419) truncated secretin receptor constructs. Each
of the truncated secretin receptor constructs translocated the YFP-tagged RAMP3 to the cell
surface (arrowheads) similar to wild type secretin receptor. These images shown are
representative of four similar experiments. Insets show the boxed regions at higher
magnification. Bar 25 μm.
Harikumar et al. Page 20













FIGURE 6. Morphological bimolecular fluorescence complementation assay of RAMP3 interaction
with the secretin receptor, determining the ability of transmembrane peptides to competitively
disrupt the complex
Shown are the representative confocal images of COS cells co-expressing YN-tagged RAMP3
and YC-tagged secretin receptor treated with or without the specified secretin receptor
transmembrane peptides at a concentration of 40μg/ml for 2 hr prior to fixation of the cells.
Cell surface fluorescence (highlighted with arrowheads) was competitively disrupted only by
TM6 and TM7 peptides. Images shown are representative of images from three similar
experiments. Insets show the boxed regions at higher magnification. Bar 25 μm.
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FIGURE 7. Morphologic fluorescence analysis of chimeric receptor association with RAMP3
Three chimeric secretin-GLP1 receptor constructs were studied for their abilities to translocate
the fluorescent RAMP3 construct to the transfected COS cell surface. Sec(GLP1TM1-3)R and
Sec(GLP1TM4-5)R behaved like wild type secretin receptor, associating with this RAMP and
translocating it to the COS cell surface. However, Sec(GLP1TM6-7)R did not have this effect,
behaving instead like the wild type GLP-1 receptor. This supports the interpretation that the
TM6 and TM7 regions of the secretin receptor are responsible for its association with RAMP3.
Insets show the boxed regions at higher magnification.Bar 25 μm.
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FIGURE 8. BRET analysis of secretin receptor-RAMP3 interaction using the truncated RAMP
construct
Shown are the static (A) and saturation (B) BRET signals obtained from COS cells
coexpressing Rlu-tagged secretin receptor with YFP-tagged amino-terminally-truncated
RAMP3. Significant BRET signals above non-specific (shown in the shaded area) are marked
**p<0.001. The values plotted represent means ± S.E.M. of data from five independent
experiments. Also shown are representative images from morphological translocation assay
(C). Confocal microscopic images were collected from COS cells coexpressing YFP-tagged
truncated RAMP3 with untagged secretin receptor. The truncated RAMP3 was able to
translocate the secretin receptor to the cell surface (arrowheads). The data marked **p<0.001
level in figure A represents significant BRET signal above the nonspecific signal shown in the
shaded area. Insets show the boxed regions at higher magnification. The values plotted
represent means ± S.E.M. of data from five independent experiments. Bar 25 μm.
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FIGURE 9. Internalization of cmyc-tagged secretin receptor following stimulation with secretin
peptide (100 nM)
Shown is internalization of the secretin receptor in transiently-transfected CHO-K1 cells
measured by loss of cell surface receptor expression in an anti-cmyc enzyme-linked
immunosorbent assay. (A) secretin receptor internalization in the presence or absence of
individual RAMPs, (B) secretin receptor internalization in the presence of NSF, in the presence
or absence of individual RAMPs and (C) secretin receptor internalization, in the presence of
NHERF1, in the presence or absence of individual RAMPs. The data plotted represent means
± S.E.M. of data from three independent experiments. Where error bars are not visible these
are contained within the plotted symbols. No RAMP3-specific alteration to responses was
observed.
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FIGURE 10. Chaperone function of RAMP3 at a trafficking-defective secretin receptor mutant
Shown are cAMP concentration-response curves to secretin stimulation of intact COS cells
expressing G241C secretin receptor mutant with or without RAMP3 (17). Shown in the inset
are the microscopic images of Alexa-secretin-labeled cells showing the increased surface
expression of the mutant receptor in the presence of RAMP3. The values plotted represent
means ± S.E.M. of data from three independent experiments. Bar 25 μm.
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FIGURE 11. Competitive inhibition of adrenomedullin action on the CLR-RAMP3 complex by
secretin receptor expression
Shown are cAMP responses to adrenomedullin (A) and secretin (B) in COS cells transfected
with a fixed amount of cmyc-CLR (50 ng) and RAMP3 (100 ng), and increasing amounts of
secretin receptor construct (noted for each curve). The values plotted represent means ± S.E.M.
of data from three or four independent experiments.
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